Mumbai, July 1 -- The board of AHEL and its subsidiary, Apollo HealthCo granted in-principle approval for the demerger of Omnichannel Pharma and Digital Health business.

The proposed structure enables direct access of omni-channel pharmacy and digital health business to the shareholders of AHEL. For every 100 shares of AHEL, the shareholders of AHEL will receive 195.2 shares of the new company, Apollo Healthtech enabling their direct participation in the value unlock.

The proposed transaction will result in the creation of the largest, integrated omni channel healthcare eco-system with a FY25 revenue of approximately Rs 16,300 crore ($ 1.9 billion) in FY25. The Apollo Healthtech is expected to achieve a revenue run rate of Rs 25,000 cro...